# OnCo record zen-3694 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/zen-3694/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "zen-3694" ;
  schema:name "ZEN-3694"@en ;
  schema:alternateName "ZEN003694"@en, "Zenith BET inhibitor"@en ;
  schema:description "ZEN-3694 is a BET inhibitor from Zenith Epigenetics being tested in NUT carcinoma, where the cancer's driving fusion is itself a BET protein, and in prostate and breast cancers."@en ;
  schema:url <https://onco.cc/drugs/zen-3694/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/BET_inhibitor> ;
  schema:citation <https://clinicaltrials.gov/study/NCT05019716>, <https://clinicaltrials.gov/study/NCT05372640> ;
  onco:status "phase-2" ;
  onco:tag "gap-fill", "owner-request" ;
  onco:modality "Oral small-molecule BET bromodomain inhibitor" ;
  onco:cancers <https://onco.cc/cancers/nut-carcinoma/>, <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/tnbc/> ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/> ;
  onco:targets <https://onco.cc/targets/brd4/> ;
  onco:companies <https://onco.cc/companies/zenith-epigenetics/> ;
  onco:trials <https://onco.cc/trials/zen-3694-platinum-nut/>, <https://onco.cc/trials/zen-3694-abemaciclib-nut/>, <https://onco.cc/trials/nct04986423/> .